Daily Stock List
New Zealand Energy Corp. (NZERF)
We are reporting on New Zealand Energy Corp. (NZERF), here at the QualityStocks Daily Newsletter.
New Zealand Energy Corp. focuses on the production, development and exploration of oil and natural gas prospects in New Zealand. The Company controls over 2 million acres of land on New Zealand's north island, including pending permits, with conventional and unconventional resources. New Zealand Energy formed in 2010 to pursue new opportunities for energy exploration resulting from the New Zealand government's growing encouragement of energy exploration. The Company lists on the OTCQX International and on the TSX Venture Exchange under the trading symbol "NZ.V".
New Zealand Energy's property portfolio collectively covers acreage in the Taranaki Basin and East Coast Basin of New Zealand's north island. Their management team has extensive experience exploring and developing oil and natural gas fields in New Zealand and Canada.
This week, New Zealand Energy provided an update on their exploration and production activities in the Taranaki Basin of New Zealand's North Island. The Company has drilled ten wells on their Eltham Permit in the Taranaki Basin, with five oil discoveries and results pending from two Mt. Messenger wells. Currently, New Zealand Energy is producing approximately 335 barrels of oil per day (bbl/d).
The Company's goal is to increase near-term production and cash flow while reducing exploration expenses. To achieve this objective, they are delaying the remaining two wells in their Eltham/Alton drill program. This is to focus on commercial opportunities in the pending acquisition of assets from Origin Energy Resources NZ (TAWN) Ltd. This decision does not diminish their view of the prospectivity of the Eltham and Alton permits. However, their intention is to focus in the near-term on lower-cost opportunities that are close to infrastructure. They expect closing of the acquisition of assets to occur in Q2-2013.
The Company's technical team has also identified five high-priority Mt. Messenger targets in the southwest corner of the petroleum licenses. New Zealand Energy has completed permitting for a new site called Waipapa (Oru Rd). They will soon start construction of the drill pad to ensure that they can move quickly to access these targets once the acquisition has closed. Commercial oil discoveries on their properties and those of their peers have confirmed the prospectivity of the Mt. Messenger formation. It remains New Zealand Energy's main exploration target in the near term.
New Zealand Energy Corp. (NZERF), closed Thursday's trading session at $0.382, up 16.78%, on 4,931 volume with 5 trades. The average volume for the last 60 days is 27,465 and the stock's 52-week low/high is $0.3271/$3.74.
Blue River Resources Ltd. (BXR.V)
Today we are highlighting Blue River Resources Ltd. (BXR.V), here at the QualityStocks Daily Newsletter.
Blue River Resources Ltd. is a mineral exploration and development company. Their focus is on copper exploration in British Columbia. The Company's projects include the Highland North Project and the Castle Copper Project. Blue River Resources' shares trade on the TSX Venture Exchange. The Company has their headquarters in Vancouver, British Columbia.
Blue River Resources' Phase I diamond drill program on the Highland North Project, conducted in September 2012 , totaled 1,182,56 meters of NQ drillcore over 5 holes (from 5 drill sites) . The program resulted in 479 samples collected and submitted for assays. Diamond drill hole BXR-12-2 intersected 39.65 meters (130 feet) grading 0.1 percent copper, from 30.85 meters (101.2 feet) to 70.05 meters (229.8 feet). Drill hole BXR-12-2 was the only hole to have reportable mineralization. The Company has no further exploration planned for the Highland North Project.
The Company holds a 100 percent interest in the 18,000-acre Castle Copper Project. This Project is 25 kilometers north of Copper Mountain Mining. The Castle project is directly north of Sego Resources' Miner Mountain property and directly south of Westar's Axe Copper Project, currently under joint venture with Xstrata Copper. Blue River drilled 3 short reconnaissance diamond drill holes in September of 2012 totaling 123 meters (407 feet); they encountered no significant mineralization. Blue River's current exploration plans for the Castle Copper project include an extensive ground IP and mag survey over the 7 kilometers of the Nicola fault that trends through the Castle property.
Today, Blue River Resources announced that they acquired an option to earn a 100 percent interest in the Mazama Copper deposit in Okanogan County, Washington. With this agreement, Blue River has agreed to pay to the vendor, upon approval by the TSX Venture Exchange, $85,000 in year one and $50,000 in each of year two and three for a total of $185,000. Additionally, Blue River has agreed to pay 500,000 shares every 3 months to a maximum 5,000,000 shares. Moreover, the Company has agreed to grant the vendor a 3 percent Net Smelter Royalty (NSR), of which 2 percent can be purchased by Blue River for $3.0 million.
Mr. Griffin Jones, President of Blue River Resources, stated, "We are very excited about the acquisition of a near-surface copper deposit in nearby Washington State. The Mazama deposit positions the Company with a development-stage asset that is relatively close to Vancouver BC. The Mazama Project is located approximately 43 kilometers (27 miles) south of Osoyoos BC".
Blue River Resources Ltd. (BXR.V), closed Thursday's trading session at $0.12, down 14.29%, on 683,600 volume. The stock's 52-week low/high is $0.06/$0.19.
Massive Dynamics, Inc. (MSSD)
Stock Stars and MonsterStocksPicks reported this month on Massive Dynamics, Inc. (MSSD), Real Pennies, SmallCapNetwork, Investor Spec Sheet, SmallCapVoice, Wallstreet Profiler, PennyDoctor, Wallstreetbuzz, MajorPennyStocks reported earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Listed on the OTC Markets' OTCQB, Massive Dynamics, Inc. is an acquirer, developer and seller of leading edge communications technology and products. The Company primarily focuses on the profitability of the oncoming universal Web 4.0 technologies. Massive Dynamics is planning to announce several Web 4.0 product advances this year. The Company has their corporate headquarters in Cupertino, California.
Web 4.0 centers mainly around systems that involve "Intelligent Interaction" with users. Massive Dynamics is integrating DYNAMIC KEYSET in Android applications and technology that will allow the use of glass surfaces to be used for Intelligent Interaction. The Company also offers their TeliPad smartphone product. The TeliPad is approximately the size of a credit card. It can be fastened to the back of a computing tablet or kept in close proximity; it works by way of Bluetooth©. The TeliPad is compatible with iOS, Android and Windows tablets.
Massive Dynamics believes that DYNAMIC KEYSET could significantly expand teacher and student Intelligent Interaction. They believe it would have near endless intelligent interaction between workers, management, computing devices and presentation devices. For Home use, there are many applications for Intelligent Interaction on glass surfaces using DYNAMIC KEYSET.
In addition, Massive Dynamics has developed the RANGER MD8. It utilizes biquad antenna technology for quality wireless signal to 8 miles away. This Product can be used in outlying areas to reach urban wireless early - or any applications in which a long-range remote receiver is required.
Yesterday, Massive Dynamics announced that they launched a new division that will acquire existing companies in the fast expanding 3D printing market. The Company has started discussions with several potential acquisition candidates who have existing 3D printers or provide required printing supplies and accessories.
Today, Massive Dynamics announced that they executed a Letter of Intent (LOI) with Forty-Two LLC, headquartered in Rochester, New York. Forty-Two develops and markets tools used to capture 3D imagery that is often used in the replication of products by way of 3D printing techniques. While the companies are working together to negotiate a definitive agreement, Massive Dynamics has the exclusive marketing rights for Forty-Two's ZS Axis 3D imaging technologies.
Massive Dynamics, Inc. (MSSD), closed Thursday's trading session at $0.678, up 5.12%, on 313,434 volume with 259 trades. The average volume for the last 60 days is 155,060 and the stock's 52-week low/high is $0.0492/$2.08.
Medisafe 1 Technologies Corp. (MFTH)
OTCPicks reported recently on Medisafe 1 Technologies Corp. (MFTH), WallStreetBeats, PennyTrader Publisher, Penny Stock Rumble did earlier, and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Medisafe 1 Technologies Corp. is a developer of patented technologies that physically prevent unauthorized administration of prescription medications. The Company works to prevent, effectively, unauthorized administration of a drug or medicinal substance by hypodermic needle. Founded in 2009, Medisafe 1 Technologies has their corporate headquarters in Jerusalem, Israel. The Company's shares trade on the OTC Bulletin Board.
Medisafe 1's vision is administering the right drug with the right dose to the right patient at the right time. They have the world's first U.S. patented technology to eliminate the administration of incorrect medicinal substances by hypodermic needle. They were granted Patent No. 7,347,841 B2 on March 25, 2008.
The Company's patented technology is a medical assembly with a locking mechanism. The intention of it is to ensure the substance cannot undergo release from the hypodermic needle without positive pre-matching between the substance and its intended patient.
The protector fits over a proportion of the medicine assembly and the protector includes a bar code and locking element. The locking element is released electronically on positive match.
Last month, the Company announced that they generated an operating profit of approximately $2M in their fourth fiscal quarter from the sale of their first non-exclusive perpetual license agreement that transfers rights for the full commercialization, marketing and distribution of their patented medicinal locking mechanism and bar-code matching system.
Mr. Jacob Elhadad, Chief Executive Officer of Medisafe 1 Technologies, said, "Upon the completion of this non-exclusive perpetual license agreement, we will be extremely pleased to be able to reward our shareholders with this special dividend. Similarly, we intend to continue to update our shareholders with further information following the sale's closing."
This month, Medisafe 1 Technologies announced that they intend to issue the one-time special dividend to all existing shareholders pursuant to the perpetual license sale of technology rights to Safecode Drug Technologies Corp. The dates of the dividend are - Ex-Dividend date for their dividend to their Shareholders on April 30, 2013, record date on May 3, 2013, and the payment date on May 6, 2013.
Medisafe 1 Technologies Corp. (MFTH), closed Thursday's trading session at $0.0024, down 4.00%, on 31,656,496 volume with 118 trades. The average volume for the last 60 days is 8,563,610 and the stock's 52-week low/high is $0.001/$0.0155.
Inscor, Inc. Corp. (IOGA)
We are highlighting Inscor, Inc. Corp. (IOGA) today, here at the QualityStocks Daily Newsletter.
Based in Nevada, Inscor, Inc. Corp. provides a variety of life insurance products in the U.S. The Company is a leading independent insurance national consulting and marketing organization of life, disability-income and long-term care insurance and other financial tools and services in addition to a broad spectrum of annuity products marketed via their financial and insurance professional advisors nationwide. Inscor's shares trade on the OTC Pink Current Information.
The Company has a two-fold focus. They develop and maintain relationships with financial professionals, including insurance brokers, financial planners, tax attorneys, and CPAs, to promote continued growth. In addition, they specialize in providing significant funding solutions using high cash-value life insurance contracts combined with low-cost financing. The modeling of insurance and financing are within the framework of a Financed Insurance Trust (FIT). This is to provide major cash flows from life insurance proceeds and cash values at little or no out-of-pocket cost.
A FIT is for protecting lifestyle, income and assets for loved-ones and for securing one's future retirement. With a FIT, the cost of permanent life insurance is financed via major lending institutions. Policy cash values provide collateral; they are later used, in part, to retire the loan including principal and interest. The policyholder's assets remain in place; they need not be used to pay insurance premiums.
Inscor's FIT OPEB (Other Post-Employment Benefits) plan is a feasible solution to providing significant cash flows to fund OPEB liabilities with little, if any, increases in out-of-pocket expenditures. The funding for retiree health care and OPEB plans often strains existing cash flows of most corporations and municipalities.
FIT plans can undergo modeling to provide significant volumes of life insurance. They can also be modeled to create substantial cash values that can be accessed to provide a tax-free income stream during retirement. Through collaboration with insurance companies, financing institutions, actuaries, and attorneys, the Company has developed FIT strategies tailored for specific market segments.
Inscor additionally offers interest rate risk management/risk control instruments, business succession, and executive compensation solutions. Furthermore, the Company offers retirement, and financial and estate planning services.
Inscor, Inc. Corp. (IOGA), closed Thursday's trading session at $0.14, up 180.00%, on 290,282 volume with 67 trades. The average volume for the last 60 days is 1,918 and the stock's 52-week low/high is $0.025/$1.10.
mPhase Technologies, Inc. (XDSL)
OTCPicks and Greenbackers reported earlier on mPhase Technologies, Inc. (XDSL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
mPhase Technologies, Inc. is introducing an innovative Smart Surface technology enabled by advancements in nanotechnology, microelectromechanical systems (MEMS) processing and microfluidics. The Company's Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. A New Jersey corporation founded in 1996, mPhase has pioneered their first Smart Surface enabled product, the mPhase Smart NanoBattery.
mPhase is a development stage company and they are in the process of commercializing the Smart NanoBattery - the new patented and patent pending battery technology based on the phenomenon of electrowetting. It offers a unique way to store energy and manage power. Features of the Smart NanoBattery include potentially infinite shelf life, environmentally friendly design, and fast ramp to power, programmable control, and direct integration with microelectronic devices.
The platform technology behind the Smart NanoBattery is a porous nanostructured material. This is used to repel and precisely control the flow of liquids. The material has a Smart Surface that can potentially undergo design for self-cleaning applications, liquid filtration/separation, water purification/desalination, as well as environmental cleanup. The Company completed a Phase II Small Business Technology Transfer Program (STTR) grant (part of the Small Business Innovation Research (SBIR) program) with the U.S. Army for continued development of a reserve Smart NanoBattery for a vital computer memory application.
In addition to the Smart Surface technology, mPhase Technologies recently introduced their first product, the mPower Emergency Illuminator. This is an award-winning product designed by Porsche Design Studio.
At the end of January, mPhase Technologies reported that they were issued patent number 8,344,543 from the U.S. Patent & Trademark Office (USPTO) for a Reserve Battery System. The invention patented generally relates to a battery system that is easily activated by way of low mechanical force. Therefore, this allows a reserve battery to be used in a broad array of consumer related and non-consumer related electrical devices.
Yesterday, the Company announced that on the heels of filing a US letter patent application for automatic dispensing of preset dosages for a drug delivery system that the Nanodermatology Society declared 2013 the year of Topical Delivery. mPhase believes that, if issued, their new application would protect the delivery of pre set dosages of a drug agent or medication topically.
mPhase Technologies, Inc. (XDSL), closed Thursday's trading session at $0.0033, down 5.71%, on 5,275,608 volume with 42 trades. The average volume for the last 60 days is 3,738,102 and the stock's 52-week low/high is $0.0004/$0.0058.
Red Giant Entertainment, Inc. (REDG)
OTPicks reported today on Red Giant Entertainment, Inc. (REDG), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Red Giant Entertainment, Inc. is an intellectual property development company with headquarters in Clermont, Florida. The intention of their properties (comic book style) is to undergo development for the comic book market and for use in other media (movies, video games, and television, novels, toys, apparel and telephone wireless applications). Red Giant's intention is to either engage in the direct production of their properties or enter into licensing agreements with others. The Company has a number of movies in various stages of production, and more are currently undergoing development.
The Company's goal for Red Giant Entertainment is for them to become the largest comic book publisher in the world. Their core business is dedicated to developing quality intellectual properties, while serving their advertisers. Red Giant is currently the largest publisher of exclusive comic book format material on the internet. The Company's print division is positioned to become the largest in the world, with an annual circulation of greater than 52 million.
Each week a new comic book targeting a different audience demographic will undergo distribution at one million copies across the network. In addition, Red Giant Entertainment has more than 36 titles in their library with thousands of characters and entire worlds to explore.
The intention of the products is for them to be available for others to purchase advertising on terms and conditions to be determined by the licensee of the product. Red Giant Entertainment intends to retain a royalty for the product and for the included advertising content. Merchandise revenue related to the product will also be available to Red Giant on terms and conditions to be negotiated between the licensee and the Company or retained by the Company.
During the three months, ended November 30, 2012, the Company's revenues were $105,937. This represents an increase of $92,760 or 704 percent from $13,177 for the three months ended November 30, 2011. The increase in revenues was due to improvement in the overall market for their products, the continuing development of their products, and penetration into the Company's market. Red Giant's net income for the three months ended November 30, 2012 was a net profit of $32,443. This is in comparison to a net profit of $3,100 during the three months ended November 30, 2011 (an increase of $29,343 or 947 percent). The increase in net income is mainly because of the increase of sales of their products.
Red Giant Entertainment, Inc. (REDG), closed Thursday's trading session at $0.133, up 33.00%, on 78,976,741 volume with 3,206 trades. The average volume for the last 60 days is 1,350 and the stock's 52-week low/high is $0.065/$0.26.
Synergetics, Inc. (SYNG)
We are highlighting Synergetics, Inc. (SYNG) today, here at the QualityStocks Daily Newsletter.
Trading on the OTC Markets' OTCQB, Synergetics, Inc. is a company managed by experienced energy innovators. The Company is focusing on environmental and technical infrastructure projects related to renewable energy and clean technologies. The Company formerly went by the name Fresh Traffic Group, Inc. They changed their corporate name to Synergetics, Inc. in August of 2012. Synergetics has their headquarters in Medford, New Jersey.
Synergetics is working to position the Company in the forefront of the clean-tech industry by combining environmentally sensitive innovations with creative management and proven industrial leadership. The Company said earlier this month that the full management team, once in place would be an entrepreneurial, market-focused, and process-oriented group with a global perspective.
The Company plans to engage creative project-specific teams of motivated professionals with innovative knowledge within their working fields. Currently, Synergetics is able to call upon a varied group of successful businesspersons, engineers, marketing, legal and financial professionals based in North America, Europe and Asia to assist in the implementation of their business plan.
Mr. Michael R. Wiechnik, President and Chief Executive Officer of the Company, said, "The Company's core business will be the development of responsible alternative energy solutions through waste and bio-energy management and the first projects will include the design, manufacture, distribution and support of community-sized biodiesel refineries. We anticipate beginning operations involving this technology in Russia; China and Europe with expansion into North America at a later time."
The Company's proprietary bio-energy production system technology will be able to process carbonaceous waste. Synergetics will also specialize in infrastructure development from "cradle to grave" for renewable energy innovation projects. They will actively work with renewable and sustainable energy networks to develop unique business models and opportunities for industrial and infrastructure projects using biomass, wind, hydro, wave, geothermal, combined heat and power (CHP), solar, as well as other emerging technologies.
Synergetics, Inc. (SYNG), closed Thursday's trading session at $0.11, up 120.00%, on 134 volume with 1 trade. The average volume for the last 60 days is 1,414 and the stock's 52-week low/high is $0.02/$0.9774.
The Guitammer Company Inc. (GTMM)
The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.16, even for the day. The stock’s average daily volume over the past 60 days is 15,985, and its 52-week low/high is $0.082/$0.35.
The Guitammer Company Inc. reported a huge move today as the company joins North America's largest buying and marketing organization, Nationwide, as a vendor. The company also announced that it will be an exhibitor at Nationwide's upcoming PrimeTime! Buying Show and Member Conference, March 3rd - 6th at the Venetian Convention Center, Las Vegas NV. On display at this year's PrimeTime show will be Guitammer's line of award-winning ButtKicker®-brand low frequency audio transducers that provide an immersive "4D" entertainment experience for audiences. In addition to the booth exhibitions, ButtKicker brand products will also be directly introduced to CEOs and owners of Specialty Electronics Nationwide and its Cantrex Canadian Division member companies on Monday morning, March 4th.
The Guitammer Company Inc. (GTMM) is a leader in low frequency sound products and technology. Its innovative and award winning line of patented ButtKicker-brand low frequency audio transducers let users feel low-frequency sound (bass). ButtKicker brand products are used around the world by leading entertainment and theater companies such as AMC, IMAX and Disney in movie theaters and attractions; by world-famous musicians; in home theaters, simulators and for car audio.
ButtKicker brand products are distributed by Pearl Drums for musicians under the trade name, "Pearl's Throne Thumper by ButtKicker", and factory installed in home theater seating by Palliser Furniture. ButtKicker brand products' patented design makes them musically accurate, powerful and virtually indestructible. The Company is headquartered in Westerville, OH.
The Guitammer Company's newly patented broadcast technology, ButtKicker LIVE! enables the excitement, impact and feeling of sporting events to be broadcast along with the sound and video. ButtKicker LIVE! puts you into the action, whether you're at home or at the event.
ButtKicker Live! technology is available for cable, satellite, fiber optic, IPTV and over-the-air broadcast and has been successfully tested with several major content (sports) providers. ButtKicker(r) and ButtKicker Live!(r) are registered trademarks of The Guitammer Company. Disclaimer
The Guitammer Company Inc. Company Blog
The Guitammer Company Inc. News:
Guitammer Joins Nationwide, North America's Largest Buying and Marketing Organization
Guitammer Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
Guitammer Third Quarter Revenue More Than Triples To $555,000
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.11, even with yesterday's close, on 13,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 67,739, and its 52-week low/high is $0.0069/$0.13.
Viscount Systems, Inc. reported today that the company has received orders to secure additional facilities owned by the British Columbia Government as part of an ongoing rollout involving hundreds of facilities where the company's revolutionary Freedom access control systems and MESH touch screen intercom panels will create a real-time bulwark from existing, standard building IT network hardware. This is yet another big rollout for the company and the mounting client base VSYS is seeing is a direct result of the incredible savings and technical superiority of the company's solutions, which are as much as 80% cheaper than traditional systems, use existing logical IT security software, and ultimately provide a better security envelope for building ingress/egress.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount’s Freedom Installed at Additional BC Government Sites
Viscount Systems Awarded Contract to Secure Large Industrial Facility
Viscount Systems Awarded Contract to Secure Additional U.S. Government Facilities
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.103, on 6,204,151 volume with 290 trades. The stock’s average daily volume over the past 60 days is 4,827,992, and its 52-week low/high is $0.0275/$0.155.
Advaxis, Inc. announced today that the company will be holding a conference call and live audio webcast Wednesday, March 6, 2013 at 5 p.m. ET to discuss ADXS's 2013 business outlook. Included in the outlook will be a discussion about progress with and plans for advancing the company's lead development program, as well as expected clinical and corporate milestones for the year, overall momentum, and continued plans for further strengthening an already robust financial position. Also on the docket will be an update regarding the Phase 2 dose escalation study of the company's lead construct, ADXS-HPV, for the treatment of cervical intraepithelial neoplasia 2/3.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis to Provide 2013 Business Outlook on March 6, 2013
Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group
Chairman and CEO of Advaxis Featured in Exclusive SmallCapVoice Interview
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.1725, up 0.41%, on 226,460 volume with 102 trades. The stock’s average daily volume over the past 60 days is 176,207, and its 52-week low/high is $0.15/$0.30.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium's Excellagen® Awarded American Podiatric Medical Association Seal of Approval, Company Also Announces Addition of a Regional Distributor for Excellagen
Cardium Announces Presentation at The 2013 Cell & Gene Therapy Forum
Cardium To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium Initiatives
The Guitammer Company, a leader in low frequency sound and creator of the award-winning line of ButtKicker®-brand audio transducers that provide an immersive “4D” entertainment experience, just announced it has joined Nationwide as a vendor and will be an exhibitor at its PrimeTime! Buying Show and Member Conference taking place March 3rd – 6th at the Venetian Convention Center, Las Vegas, NV.
ButtKicker brand products will be on display at Guitammer’s booth, #4240, and in two locations at Nationwide’s SOLUTIONS Central. Notably, they will be a ““Featured SOLUTION” during the event.
“We are excited to offer ButtKicker brand products to our members,” stated Jeannette Howe, Executive Director of Specially Electronics Nationwide. “There has been an enthusiastic ‘buzz’ about ButtKicker leading up to the PrimeTime! show and I am very confident that this new partnership between Guitammer, Nationwide and our members will be a long lasting success for all involved.”
She continued, “I am especially pleased that ButtKicker brand products will be demonstrated in the SOLUTIONS Central, a must-visit destination for members PrimeTime! experience. Imagine a simulated showroom space featuring live operating examples of Nationwide’s leading edge Member Services along with specialists who can demonstrate their capabilities and answer members’ questions.”
Mark Luden, President of Guitammer, added, “We are appreciative of the opportunity to become part of Nationwide and look forward to significantly expanding our dealer network and retail footprint throughout the US and Canada.”
In addition to exhibiting ButtKicker brand products at its own booth and at SOLUTIONS Central, Guitammer will be introducing its product lineup to CEOs and owners of Specialty Electronics Nationwide and its Cantrex Canadian Division member companies during the conference.
For more information, visit www.Guitammer.com
Viscount Systems, Canadian-based designer and producer of commercial access control and security products for thousands of sites in over 30 countries, is introducing the world to a new-generation of commercial security.
The company is eliminating the need for the expensive and difficult to upgrade traditional approach to access control by applying advanced software and communication technologies to the process, allowing the deployment of access control on IT platforms. It’s an approach that most existing security companies have trouble with because it is fundamentally different, and they don’t have the needed IT product development and engineering skills, nor access and relationships with the “IT-side” of enterprise and government organizations.
Viscount, on the other hand, has a leadership and advisory team that is well-versed in these technologies, as well as the security industry in general.
• Steve Pineau (CEO) has been a visionary leader with Viscount since 1997 and anticipated the paradigm shift currently underway in the security industry. He thoroughly understands the operational, technological, and financial aspects of the business.
• Dennis Raefield (COO), past President of the Honeywell Access Systems division, which operates at a $100 million annual revenue level, and past President of Pinkerton Systems Integration, is an expert in the integration of large security systems.
• Shayne Bates (Advisory Team) has a long history as a thought leader in the unification of physical and logical access control, and has emphasized Active Directory in his approach, working closely with Microsoft in developing cloud strategy.
• Ron Martin (Advisory Team) is known throughout the security industry for his expertise in Identity Management and Physical Access Control systems.
• Paul Brisgone (Board Member) has 34 years of experience with ADT, most recently as the VP of their Federal Systems Division.
• Robert Liscouski (Board Member) was the first Assistant Secretary for the US Department of Homeland Security.
• Paul Goldenberg (Board Member) was appointed to the Homeland Security Advisory Council by Janet Napolitano and has a distinguished career in criminal justice.
For additional information, visit www.Viscount.com
Advaxis, a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases, this morning told investors that a conference call and live audio webcast has been scheduled for Wednesday, March 6, 2013. Starting at 5 p.m. ET, management will discuss the company’s 2013 business outlook, including progress with and plans for advancing its lead development program, expected clinical and corporate milestones for the year, and its momentum and continued plans for further strengthening its financial position.
The biotech will also provide an update on the timing of the data release from the second of three dose cohorts in Lm-LLO-E7-07, a randomized, single blind, placebo controlled Phase 2 dose escalation study assessing the safety and efficacy of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (CIN) 2/3. In a prior release, Advaxis said it anticipated reporting this data earlier in the first quarter of 2013. However, data are still being collected and analyzed from some of the clinical trial sites, therefore the results from Cohort 2 will instead be announced early in the second quarter.
Those who wish to join the call should do so by dialing 800-688-0836 (U.S./Canada) or 617-614-4072 (international). When requested, interested parties should enter code 70014771. A live audio webcast can also be accessed via http://www.advaxis.com/news/events-presentations. An archived version will be available on the Web site for 30 days.
Investors can replay the call by telephone for seven days beginning at 8:00 p.m. ET on March 6, 2013. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 55408167.
Let us hear your thoughts: Advaxis, Inc. Message Board
Coronary artery disease – the No. 1 cause of death worldwide – kills more than 17 million people around the world each year. It’s easy to skim over the statistics when “death” dominates global headlines. We are desensitized to a bold and ruthless serial killer among us that has literally stopped millions of hearts dead in their tracks. The real clincher is that this killer can be stopped.
Health and active living advocates have exposed cardiovascular disease for what it really is – an often self-inflicted disease that could be prevented by adhering to a healthy lifestyle. Despite an increasingly educated population, the human race, collectively, isn’t ready to forfeit poor eating choices and wise-up to heart health. That’s why regenerative medicine company Cardium Therapeutics is conducting countless hours of research and development to offer a non-conventional approach to coronary artery disease.
Traditional treatments for heart disease ranges from drug therapy to highly invasive bypass surgeries, stents, angioplasty, and grafts. Cardium’s counter solution is a one-time, non-surgical gene-based treatment option called Generx, administered using a standard cardiac infusion catheter.
Generx is designed to work with and enhance the body’s natural healing process by stimulating blood vessel growth in the heart, which in turn generates blood flow. Clinical studies of Generx show improved cardiac perfusion (blood flow, in this case) within eight weeks. To-date, Generx has completed four randomized clinical studies at more than 100 medical centers in the United States and Western Europe.
Cardium plans to enroll 100 men and women with myocardial ischemia from coronary artery disease for the upcoming ASPIRE phase 3 clinical study to evaluate the Generex’ safety and efficacy. The ASPIRE study will mark the fifth clinical study under Generex’ clinical development program, which will prepare the company to seek regulatory approval from the Russian Health Authority.
For more information, visit www.cardiumthx.com
Today's Top 3
1-2-3 Stock Alerts
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) to Provide 2013 Business Outlook on March 6, 2013
- Bergamo Acquisition Corp. (BGMO) Provides Authenticated Documentation to Confirm Bank Deposits
- Consorteum Holdings, Inc. (CSRH) Reaches Funding Agreement With Private Equity Group
- Cardium Therapeutics, Inc. (CXM) Announces Presentation at The 2013 Cell & Gene Therapy Forum
- Duma Energy Corp. (DUMA) Receives 1.1 Billion Barrel P10 Estimate for Namibia Concession
- GlobalWise Investments, Inc. (GWIV) CEO to Speak at Technology United Executive Conference
- HII Technologies, Inc. (HIIT) Announces Engagement of QualityStocks Investor Relations Services
- International Stem Cell Corp. (ISCO) Strengthens Intellectual Property Portfolio
- Loans4Less.com, Inc. (LFLS) Engages CPA Firm to Audit Financials
- Rafarma Pharmaceuticals, Inc. (RAFA) Receives General License for Pharmaceutical Products Starts Mfg. 3 New Products
- Rainbow Coral Corp. (RBCC) Opens Talks to Help Develop Revolutionary Breakthrough in $60 Billion Drug Delivery Market
- The Guitammer Company Inc. (GTMM) Joins Nationwide, North America's Largest Buying and Marketing Organization
- Viaspace, Inc. (VSPC) 25 Acres of Giant King Grass Shipped and Growing in St. Croix
- Viscount Systems, Inc. (VSYS) Freedom Installed at Additional BC Government Sites
- VistaGen Therapeutics, Inc. (VSTA) Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium